ClinicalTrials.gg
CompletedNCT07204678REAL-PRECISEUpdated Mar 13, 2026

PMCF Study of Precise Pro Rx for Carotid Artery Disease

An observational study in Carotid Artery Stenosis, sponsored by Cordis US Corp.. Completed at 4 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by Cordis US Corp. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
199
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Carotid Stenosis with a site in Italy — 3 open to participants now, 5 under way, none of them phase 3. Carotid Stenosis · Italy.

Enrollment
7th of 11
199 · median 200
Started
2025
the only one that year
Observational
11 of 22
3 open now
Registered
21st of 22
by date

Among the 22 studies in Carotid Stenosis with a site in Italy, this one is the 7th largest by enrollment of the 11 observational ones that give a count, is the only one that started in 2025, is one of 11 observational ones, and was the 21st registered.

Carotid Stenosis

369 studies on the registry are indexed under Carotid Stenosis; 88 are open to participants now.

Browse Carotid Stenosis studies →

Open to participants now

3 of the 22 studies in Carotid Stenosis with a site in Italy are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 62 Carotid Stenosis studies recruiting now, 39 (63%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Carotid Stenosis with a site in Italy, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate long-term clinical safety and performance of the PRECISE PRO RX Nitinol Stent System to treat stenotic lesions of the carotid arteries.

Read the detailed description

The REAL-PRECISE study is a multi-center, non-randomized, observational analysis of retrospective data collected on subjects treated with PRECISE PRO Rx Nitinol Stent System. The purpose of this study is to evaluate the long-term (5-year) safety and performance of PRECISE PRO Rx Nitinol Stent System in subjects with stenotic lesions of the carotid arteries. The study is conducted in up to 15 European study sites in approximately 3 countries with high volume use of PRECISE PRO Rx. The enrollment and data collection takes approximately 4-6 months.

03

Conditions studied

  • Carotid Artery Stenosis

Browse trials for

Keywords

  • Carotid artery stenosis
  • PRECISE PRO Rx Nitinol Stent System
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects treated with the PRECISE PRO Rx Nitinol Stent System according to the Instructions for Use for treatment of carotid artery stenosis.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

NOTE: This is a RETROSPECTIVE study designed to collect outcomes on subjects who were already treated with the study device.

Inclusion criteria

Inclusion Criteria:

  • Subjects treated with the PRECISE PRO Rx Nitinol Stent System according to the Instructions for Use for treatment of carotid artery stenosis
  • If an EC-approved waiver is not obtained, then documented informed consent from the subject or legal representative granting permission to share the subject's clinical data

Exclusion criteria

Exclusion Criteria:

  • Women who were pregnant or lactating at the time of the procedure
  • Pediatric subjects (\<18 years of age) at the time of the procedure
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
199 participants (actual)
Patient registry
No

Groups and cohorts

  • Subjects treated with the PRECISE PRO Rx Nitinol Stent System

    Subjects treated with the PRECISE PRO Rx Nitinol Stent System according to the Instructions for Use for treatment of carotid artery stenosis

    Device: PRECISE PRO Rx Nitinol Stent System

Interventions

  • DevicePRECISE PRO Rx Nitinol Stent System

    The Cordis PRECISE PRO Rx Nitinol Stent System is a single-use device consisting of an endovascular stent and sheath delivery system, intended to deliver a self-expanding endovascular stent to the carotid artery(ies). The stent component imparts an outward radial force on the luminal surface of the vessel wall restoring vascular patency. The Cordis PRECISE PRO Rx Nitinol Stent System is indicated for use in patients with stenotic lesions of the carotid artery(ies).

06

What researchers measure

Primary outcomes

  1. Performance Endpoint - Technical Success

    Achievement of a final residual stenosis of \<30% at the target lesion using any percutaneous method at the conclusion of the index procedure

    Time frame: At the conclusion of the index procedure

  2. Performance Endpoint - Target Lesion Revascularization (TLR) at 12 months

    A repeat revascularization procedure performed at the original treatment site due to restenosis of ≥50% at the target lesion (as confirmed by quantitative angiography) in the presence of symptoms or ≥80% in the absence of symptoms

    Time frame: At 12 months

  3. Safety Endpoint - All-Cause Mortality

    All site-reported events of all-cause mortality

    Time frame: Through 5 years

  4. Safety Endpoint - Myocardial Infarction

    All site-reported events of myocardial infarction

    Time frame: Through 5 years.

  5. Safety Endpoint - Major Stroke

    A major stroke is defined as a cerebrovascular accident

    Time frame: Through 5 years

  6. Safety Endpoint - Minor Stroke

    A minor stroke is defined as a transient ischemic attack

    Time frame: Through 5 years

  7. Safety Endpoint - Thrombosis

    All site-reported events of thrombosis

    Time frame: Through 5 years

Other outcomes

  1. Stent Patency

    The stent patency is defined as 30% stenosis immediately post-stent placement and \< 50% stenosis long-term

    Time frame: Through 5 years

  2. All adverse events

    All adverse events reported by sites

    Time frame: Through 5 years

  3. In-Stent Restenosis (ISR)

    All site-reported events of In-Stent Restenosis (ISR) evaluated through any imaging assessment performed

    Time frame: Through 5 years

07

Study locations

4 sites
  • University Hospital Tulln
    Tulln, 3430, Austria
  • Hospital Pellegrin Bordeaux
    Bordeaux, France
  • Pineta Grande Hospital
    Castel Volturno, Italy
  • I.R.C.C.S. San Donato Polyclinic
    Milan, Italy
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2025 to primary completion in Feb 2026, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2025
First posted
Oct 2, 2025
StartActual
Oct 30, 2025
Primary completionActual
Feb 27, 2026
CompletionActual
Feb 27, 2026
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07204678
Lead sponsor
Cordis US Corp.
Collaborators
Rede Optimus Hospitalar SA
Responsible party
Sponsor
First posted
Oct 2, 2025
Start date
Oct 30, 2025
Primary completion
Feb 27, 2026
Completion
Feb 27, 2026
Last update
Mar 13, 2026

Study contacts

Nusrath Sultana
study director · Cordis US Corp.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion